Finasteride - An update and review

Cutis

Volumn 64, Issue 3, 1999, Pages 167-172

  Cather, Jennifer Clay ^a   Lane, Deanna ^a   Heaphy Jr , Michael R ^a   Nelson, Bruce R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR; FINASTERIDE; OXIDOREDUCTASE; TESTOSTERONE;

ALOPECIA; ANIMAL; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; METABOLISM; PREGNANCY; REVIEW;

ALOPECIA; ANIMALS; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FEMALE; FINASTERIDE; HUMANS; MALE; OXIDOREDUCTASES; PREGNANCY; TESTOSTERONE;

EID: 0033194437     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Imperato-McGinley J, Guerrero L, Gautier T, et al: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186: 1213-1215, 1974.
2. Walsh PC, Madden JD, Harrod MJ, et al: Familial incomplete male pseudohermaphroditism, type 2. N Engl J Med 291: 944-949, 1974.
3. Amichai B, Grumvald MH, Sobel R: 5α-reductase inhibitors - a new hope in dermatology? Int J Dermatol 36: 182-184, 1997.
4. Jenkins EP, Andersson S, Imperato-McGinley J, et al: Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin invest 89: 293-300, 1992.
5. Gormley GJ: Finasteride: a clinical review. Biomed Pharmacother 49: 319-324, 1995.
6. Anonymous: Propecia and Rogaine extra strength for alopecia. Med Lett Drugs Ther 40: 25-27, 1998.
7. Whiting DA: Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 28: 755-763, 1993.
8. Grino P, Stoner E: Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. Eur Urol 25(suppl 1): 24-28, 1994.
9. Geller J: Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 27: 267-273, 1995.
10. Stoner E, the Finasteride Group: Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43: 284-294, 1994.
11. Bergfeld WF: Androgenetic alopecia: an autosomal dominant disorder. Am J Med 98: 95S-98S, 1995.
12. Nelson BR, Johnson TL: Current management of androgenetic alopecia. In, Advances in Otolaryngology Head and Neck Surgery (Krause CJ, Brackmann DE, eds), vol 7, pp 271-302. New York, CV Mosby, 1994.
13. Drake LA, Dinehart SM, Farmer ER, et al: Guidelines of care for androgenetic alopecia. J Am Acad Dermatol 35: 465-469, 1996.
14. Kaufman KD: Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 14(4): 697-711, 1996.
15. Sawaya ME: Clinical updates in hair. Derm Clinics 15: 37-43, 1997.
16. Bingham KD, Shaw DA: The metabolism of testosterone by human male scalp. J Endocr 57: 111-121, 1973.
17. Schweikert HU, Wilson JD: Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab 38: 811-819, 1974.
18. Sawaya ME, Price VH: Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109(3): 296-300, 1997.
19. Sawaya ME, Price VH, Harris KA, et al: Human hair follicle aromatase activity in females with androgenetic alopecia. J Invest Dermatol 94: 575, 1990.
20. Rittmaster RS: Finasteride. N Engl Med 330: 120-125, 1994.
21. Steiner JF: Finasteride: a 5α-reductase inhibitor. Clin Pharm 12: 15-23, 1993.
22. Hibberts NA, Howell AE, Randall VA: Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 156(1): 59-65, 1998.
23. Steiner JF: Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30: 16-27, 1996.
24. Chen W, Zouboulis CC, Orfanos CE: The 5α-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 193:177-184, 1996.
25. Stone S: Dialogs in dermatology, volume 42 (audiotape). J Am Acad Dermatol 29: 554, 1998.
26. Tian G, Stuart JD, Moss ML, et al: 17β-(n-tertbutylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5α-reductase I. Biochemistry 33: 2291-2296, 1994.
27. Dallob AL, Sadick NS, Unger W, et al: The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 79: 703-706, 1994.
28. Kaufman KD, DeVillez R, Roberts J, et al: A 12 month pilot clinical study of the effects of finasteride on men with male pattern baldness (Abstract 550). J Invest Dermatol 102: 615, 1994.
29. Waldstreicher J, Fiedler V, Hordinsky M, et al: Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness (Abstract 549). J Invest Dermatol 102: 615, 1994.
30. Uno H, Cappas A, Brigham P: Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol 16: 657-668, 1987.
31. Diani AR, Mulholland MJ, Shull KL, et al: Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 74: 345-350, 1992.
32. Brigham PA, Cappas A, Uno H: The stumptailed macaque as a model for androgenetic alopecia: effects of topical minoxidil analyzed by use of folliculogram. Clin Dermatol 6: 177-187, 1988.
33. Rhodes L, Harper J, Uno H, et al: The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 79: 991-996, 1994:
34. Volpi R, Maccarini PA, Boni S, et al: Case report: finasteride-induced gynecomastia in a 62-year-old man. Am J Med Sci 309: 322-325, 1995.
35. Carlin BI, Seftel AD, Resnick MI, et al: Finasteride induced gynecomastia. J Urol 158: 547, 1997.
36. Pearce G, Wilton L, Kubota K, et al: An observational cohort study of finasteride (Proscar) in 14, 722 patients (Abstract). Presented at the 11th International Conference on Pharmacoepidemiology, Montreal, August 29, 1995.
37. Green L, Wysoski DK, Fourcroy JL: Gynecomastia and breast cancer during finasteride therapy. N Eng J Med 335: 823, 1996.
38. Thomas DB: Breast cancer in men. Epidemiol Rev 15: 220-231, 1993.
39. Haan J, Hollander JMR, van Duinen SG, et al: Reversible severe myopathy during treatment with finasteride. Muscle Nerve 20: 502-504, 1997.
40. Matzkin H, Chen J, Weisman Y, et al: Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol 37: 432-436, 1992.
41. Stoner E, Round E, Ferguson D, et al: Clinical experience of the detection of prostate cancer in patients with BPH treated with finasteride. J Urol 151: 1296-1300, 1994.
42. Moghetti P, Castello R, Magnani CM, et al: Clinical and hormonal effects of 5α-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 79: 1115-1121, 1994.